Block & Leviton is investigating Pasqal Holding for potentially misleading investors about its involvement in a French defense quantum-computing program. Pasqal announced ending its participation after the first phase, describing it as an "evolution" toward commercial work, but earlier reports downplayed the risk of ending the defense relationship. The stock dropped 7.4% after the announcement. The investigation focuses on when Pasqal's leadership knew about the program's outcome and if investors should have been informed sooner. Investors who lost money may be eligible to recover losses through legal action.
Pasqal Holding is under investigation related to its quantum-computing program disclosures. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 12, 2026 00:11 WIB: out of 150 priced US tech stocks, 104 rose and 46 fell. Notable movers include HP Inc (HPQ) down 6.91% with a typical hold time of 69 days and 90% buy order activity, Akamai Technologies (AKAM) up 6.00% with a 44-day hold time, and Cloudflare Inc (NET) up 5.65% with a 61-day hold time and 64% sell order activity.
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
Remittix announced its final presale price for the RTX token at $0.46, set as the minimum exchange launch price for its market debut on November 24, 2026. Currently, RTX is available at $0.23 during the ongoing presale stage, with the project nearing...
Injective (INJ) surged 10% amid increased buying pressure and notable exchange outflows, signaling renewed trader interest. Positive funding rates and rising open interest indicate bullish positioning, while ongoing ETF applications and an updated wh...
A class action lawsuit has been filed against Chemours Company and some of its officers for allegedly overstating demand for their Opteon products and providing misleading financial guidance during the period from February to August 2026. The lawsuit...
